Chalcogen Bonded Directly To The Hetero Ring Patents (Class 549/399)
  • Patent number: 10793482
    Abstract: Compounds, including chelated compounds, which may be used for the delivery of nutrients and micronutrients to plants are provided. In addition, processes for preparing such compounds, compositions comprising such compounds, and methods for delivering nutrients and micronutrients to plants with such compounds are provided.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 6, 2020
    Assignee: Spero Energy, Inc.
    Inventors: Mahdi M. Abu-Omar, Basudeb Saha, Ian Klein
  • Patent number: 10501431
    Abstract: A selenium-enriched tea polyphenol selenide, has such a structure as wherein R1 is alkali metal ion and selenium coordination complex, and R2?H, or A method for preparing the selenium-enriched tea polyphenol selenide, comprises: A) reacting tea polyphenol with at least one inorganic metallic alkali, to obtain tea polyphenol hydroxy acid salt; and B) reacting the tea polyphenol hydroxy acid salt with SeO2, to obtain the selenium-enriched tea polyphenol selenide.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: December 10, 2019
    Assignee: Shanghai Ai Qi Ecological Technology Co., Ltd.
    Inventors: Gong Chen, Kunyuan Song
  • Patent number: 10221441
    Abstract: A compound having the formula: wherein each R1 is independently H or D; R2 is alkyl or cycloalkyl; R3 is a H, alkyl, cycloalkyl, heterocycloalkyl, or carboxylate; E is NR4 or O; R4 is H or alkyl; n is an integer from 1 to 20; and C* represents a natural distribution of 12C and 13C, or enrichment with 13C.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: March 5, 2019
    Assignee: Cabridge Isotope Laboratories, Inc.
    Inventors: William Wakefield Wood, Jeffery Allen Gladding
  • Patent number: 10017489
    Abstract: The present invention opens to the public a method to prepare a benzopyran compound and its use for treating pulmonary fibrosis. A benzopyran compound has a structure (I): in which: R1 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R2 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R3 represents hydrogen, or C1-C4 alkyl; and n is any integer of 1-4, wherein the benzopyran compound is derived from a broth of Streptomyces xiamenensis CGMCC No. 5675 by extraction, separation and purification. The derivatives of xiamenmycin made from the present invention have a higher bioactivity to suppress the proliferation of normal human lung fibroblast, and medicinal products containing the same are useful in the treatment of pulmonary fibrosis.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: July 10, 2018
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Minjuan Xu, Jun Xu, Zhigang Zhang, Yahui Wang
  • Patent number: 9975869
    Abstract: The present invention provides novel analogs of epicatechin and related polyphenols, their variously functionalized derivatives, process for preparation of the same, composition comprising these compounds and their method of use.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: May 22, 2018
    Assignee: SPHAERA PHARMA PVT. LTD.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Kumar Santosh Rai, Sarbjit Singh, Ishwar Rakesh Patil
  • Patent number: 9957245
    Abstract: The objective/problem addressed by the present invention is to provide a novel technique pertaining to theaflavins synthesis. The present invention pertains to: a theaflavins synthesis catalyst characterized in having a base comprising an inorganic material, and metal nanoparticles anchored to the base, said particles measuring 0.5-100 nm in diameter; and a theaflavins synthesis method in which the catalyst is used.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 1, 2018
    Assignee: NBC MESHTEC INC.
    Inventors: Yoshie Fujimori, Tsuruo Nakayama, Tomokazu Nagao
  • Patent number: 9914718
    Abstract: An anhydrous crystalline form of S-equol has been discovered. Form I, the anhydrous crystalline form of S-equol has been isolated and characterized for the first time. As compared to other forms of S-equol, such as the known hydrate or other solvate forms, the anhydrous crystalline form of S-equol has improved properties.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 13, 2018
    Assignee: AUSIO PHARMACEUTICALS, LLC
    Inventor: Richard L. Jackson
  • Patent number: 9808023
    Abstract: Provided is a process for producing a tea extract having a high recovery rate of non-polymer catechins, a low caffeine content and an improved taste and color tone. As one embodiment of this invention provides, there is provided a process for producing a purified tea extract by adsorbing a tea extract on a synthetic adsorbent, bringing an aqueous solution of an organic solvent or a basic aqueous solution into contact with the synthetic adsorbent to elute non-polymer catechins, and then bringing the eluate into contact with activated carbon in an aqueous solution of an organic solvent.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: November 7, 2017
    Assignee: Kao Corporation
    Inventors: Eizo Maruyama, Yukiteru Sugiyama, Kenichi Shikata, Keiji Shibata, Hideaki Ueoka
  • Patent number: 9708283
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: July 18, 2017
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • Patent number: 9375416
    Abstract: Providing a compound capable of continuously taking and having a vascular endothelial function improving effect by enhancing NO function from the vascular endothelial cells. A compound represented by Formula (I) wherein R1, R2, R3 and R4 are each independently H or a gallate group, a vascular endothelial function improving agent, food and drink or pharmaceutical composition containing the compound.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: June 28, 2016
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Yuko Fukui, Mai Imamoto
  • Patent number: 9309215
    Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 12, 2016
    Assignee: UCB PHARMA GMBH
    Inventor: Claus Meese
  • Patent number: 9198895
    Abstract: Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: December 1, 2015
    Assignee: MEI Pharma, Inc.
    Inventors: Andrew Heaton, Alan Husband
  • Patent number: 9192185
    Abstract: The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. The present invention makes it possible to efficiently obtain useful components containing equol from the fermented soybean hypocotyl by subjecting an equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution as an extractant. The present invention reduces the content of saponin, which causes an unpleasant taste, by sequentially subjecting the equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution and ethanol, while efficiently extracting equol and glycitein.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: November 24, 2015
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michiaki Tominaga, Takao Taki, Toshiaki Matsumoto, Izumi Hanya, Takuma Imada, Kunihiko Matsuoka, Takuya Kishimoto, Yuko Uchiyama, Hiromasa Tsuneishi, Machiko Tsuji, Tania Valdes-Gonzalez, Kentaro Tadano, Kyoko Kameda
  • Patent number: 9169230
    Abstract: A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: October 27, 2015
    Assignees: THE HONG KONG POLYTECHNIC UNIVERSITY, WAYNE STATE UNIVERSITY, UNIVERSITY OF SOUTH FLORIDA, McGILL UNIVERSITY
    Inventors: Tak-Hang Chan, Wai-Har Lam, Larry Ming-Cheung Chow, Qing Ping Dou, Deborah Joyce Kuhn, Aslamuzzaman Kazi, Sheng Biao Wan, Kristin R. Landis-Piwowar
  • Publication number: 20150139915
    Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Stefan Worgall, Tilla S. Worgall
  • Publication number: 20150140605
    Abstract: The invention includes a selective method of modifying the N-terminus of a protein using an aminoacyl tRNA transferase. In certain embodiments, the method comprises contacting a solution of the protein or peptide with a transferase and a derivative of a molecule, whereby the N-terminus of the protein or peptide is derivatized with the molecule.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 21, 2015
    Inventor: E. James Petersson
  • Publication number: 20150141424
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 21, 2015
    Inventors: Qingping ZENG, Andras TORO, John Bruce PATTERSON, Warren Stanfield WADE, Zoltan ZUBOVICS, Yun YANG, Zhipeng WU
  • Publication number: 20150133681
    Abstract: The invention provides methods of purifying and quantifying procyanidin oligomers from cocoa-containing sources. The methods advantageously provide ways to isolate commercially useful quantities of a range of procyanidin oligomers.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Jan Glinski, W. Jeffrey Hurst
  • Patent number: 9018375
    Abstract: The present invention provides PI3K protein kinase modulators of formula (I): wherein R, R1, R2, L1, Cy1, Cy2 and n are as described herein, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: April 28, 2015
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
  • Patent number: 9018248
    Abstract: The present disclosure relates to fatty acid derivatives of green tea catechins including epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), epigallocatechin gallate (EGCG) and their epimers (e.g., catechin, catechin gallate, gallocatechin, gallocatechin gallate) or their mixtures and/or green tea extracts.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 28, 2015
    Assignee: Genesis Group Inc.
    Inventors: Fereidoon Shahidi, Ying Zhong
  • Publication number: 20150104387
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 16, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
  • Patent number: 8987480
    Abstract: The present invention relates to a process of separating chiral isomers of chroman compounds, particularly tocopherols and tocotrienols as well as the esters and intermediates thereof. It has been found that this process allows a separation of the desired isomer with a higher yield and enables the use of the non-desired isomers in a very efficient way. Said process is particularly useful when implemented in an industrial process. Furthermore, it has been found that this process allows using isomer mixtures as they result from traditional industrial synthesis.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: March 24, 2015
    Assignee: DSM IP Assets B.V.
    Inventors: Gerhard Schiefer, Thomas Netscher, Alexander Lucia Leonardus Duchateau
  • Publication number: 20150080462
    Abstract: The present invention features methods for treating or preventing conditions, diseases, or disorders related to oxidative stress. In one embodiment, the method increases Nrf2 biological activity or expression. In particular, the invention provides for the treatment or prevention of diseases relating to oxidative stress including emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia and neurodegenerative disorders, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia, cognitive deficits and neurodegenerative disorders.
    Type: Application
    Filed: August 4, 2014
    Publication date: March 19, 2015
    Inventors: Shyam Biswal, Sylvain Dore, Rajesh Kumar Thimmulappa, Tirumalai Rangasamy, Yoshihito Sakata, Zahoor Ahmad Shah, Hean Zhuang, Anju Singh
  • Publication number: 20150051270
    Abstract: A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as here in below defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituen
    Type: Application
    Filed: February 15, 2013
    Publication date: February 19, 2015
    Inventors: Shailesh Mistry, Etíenne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
  • Patent number: 8957109
    Abstract: Chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: February 17, 2015
    Assignee: MEI Pharma, Inc.
    Inventors: Andrew Heaton, Alan Husband
  • Publication number: 20150037811
    Abstract: The invention is directed to dual-analyte fluorescent chemosensors for the direct detection and visualization (imaging) of neurotransmitters released upon exocytosis. The inventive sensor exploits the high concentration of neurotransmitters (e.g., glutamate, norepinephrine, and dopamine) and capitalizes upon the pH gradient between the vesicle and synaptic cleft.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Inventors: Timothy E. Glass, Kevin D. Gillis, Kenneth S. Hettie, Jessica L. Klockow
  • Patent number: 8946288
    Abstract: The invention discloses the uses of hydroxyl polymethoxylflavones and derivative thereof that are relative to inhibit adipogenesis and lower lipid accumulation, wherein the hydroxyl polymethoxylflavones is obtained from the peels of Citrus genus plants. Therefore, the hydroxyl polymethoxylflavones that of a therapeutically effective amount not only can be a medical compound for treatment obesity or fatty liver, but also can be a food element.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: February 3, 2015
    Assignees: Greenyn Biotechnology Co., Ltd.
    Inventors: Min-Hsiung Pan, Chia-Li Wu
  • Patent number: 8946456
    Abstract: The present invention regards an improved and industrially advantageous process for the preparation of the 2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called “feso chromenyl” and (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, also called “(R)-feso deacyl”, which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine fumarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate “(R)-feso deacyl”, called form B.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: February 3, 2015
    Assignee: Chemi S.p.A.
    Inventors: Umberto Ciambecchini, Stefano Turchetta, Lorenzo De Ferra, Maurizio Zenoni
  • Publication number: 20150025251
    Abstract: The invention provides a chroman derivative represented by the following Formula (I) that enables the production of an SMTP compound having a desired structure: wherein, in Formula (I), each of Y1 and Y2 independently represents a hydrogen atom, a hydroxy group, an alkoxy group, an aryloxy group, or a halogen atom; each of R1 and R2 independently represents a hydrogen atom, an alkyl group, an aryl group, an acyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, or a carbamoyl group; L represents an aliphatic hydrocarbon group having from 4 to 10 carbon atoms; each X independently represents a hydroxy group or a carboxy group; and n represents an integer from 0 to 2.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 22, 2015
    Applicant: TMS CO., LTD.
    Inventors: Keiji Hasumi, Eriko Suzuki, Yuuichi Nishimura, Yoshikazu Kitano, Keiko Hasegawa, Naoko Nishimura, Kohta Tsujihara
  • Patent number: 8937187
    Abstract: The invention relates to compounds of formula (I): The invention likewise relates to a cosmetic method for depigmenting, lightening and/or whitening keratin materials, more particularly the skin, that utilizes these compounds.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: January 20, 2015
    Assignee: L'Oreal
    Inventor: Xavier Marat
  • Publication number: 20150004545
    Abstract: A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R1, R2, R3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NRa—. Ra represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A? represents —SO3? or —CO2?. M+ represents a monovalent onium cation.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Applicant: JSR CORPORATION
    Inventors: Hayato NAMAI, Norihiko IKEDA, Takanori KAWAKAMI
  • Publication number: 20140371471
    Abstract: A method for dynamic enhancement of chemical reactions by nanomaterials under hard X-ray irradiation. The nanomaterials were gold and platinum nanoparticles, and the chemical reaction employed was the hydroxylation of coumarin carboxylic acid. The reaction yield was enhanced 2000 times over that predicted on the basis of the absorption of X-rays only by the nanoparticles, and the enhancement was found for the first time to depend on the X-ray dose rate. The maximum turnover frequency was measured at 116×10-4 s-1 Gy-1. We call this process chemical enhancement, which is defined as the increased yield of a chemical reaction due to the chemical properties of the added materials. The chemical enhancement described here is believed to be ubiquitous and may significantly alter the outcome of chemical reactions under X-ray irradiation with the assistance of nanomaterials.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 18, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Ting Guo
  • Patent number: 8906958
    Abstract: The invention relates to certain compounds, salts of these compounds and mixtures containing or consisting of two or more such compounds, two or more such salts or one or more such compounds and one or more such salts, each for use in a method for the prophylaxis and/or treatment of inflammation, in particular of inflammation of the skin.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: December 9, 2014
    Assignee: Symrise AG
    Inventors: Katharina Reichelt, Jakob Ley, Marcus Götz, Maria Blings
  • Patent number: 8901166
    Abstract: Providing a compound capable of continuously taking and having a vascular endothelial function improving effect by enhancing NO function from the vascular endothelial cells. A compound represented by Formula (I) wherein R1, R2, R3 and R4 are each independently H or a gallate group, a vascular endothelial function improving agent, food and drink or pharmaceutical composition containing the compound.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: December 2, 2014
    Assignee: Suntory Holdings Limited
    Inventors: Yuko Fukui, Mai Imamoto
  • Publication number: 20140343303
    Abstract: Providing a compound capable of continuously taking and having a vascular endothelial function improving effect by enhancing NO function from the vascular endothelial cells. A compound represented by Formula (I) wherein R1, R2, R3 and R4 are each independently H or a gallate group, a vascular endothelial function improving agent, food and drink or pharmaceutical composition containing the compound.
    Type: Application
    Filed: July 30, 2014
    Publication date: November 20, 2014
    Inventors: Yuko FUKUI, Mai IMAMOTO
  • Publication number: 20140329279
    Abstract: Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 6, 2014
    Inventors: Min Wang, Patrick M. Hossler, Sean W. McDermott, Christopher Racicot, Kofi Chemfe, John Fann
  • Publication number: 20140315993
    Abstract: The invention relates to extracts, in particular non-nutrient phytochemicals, form sugar cane or sugar beet waste products, such as molasses, sugar mud and bagasse, which have Glycemic Index (GI) lowering properties and their use as sweeteners and in foods containing sugar.
    Type: Application
    Filed: February 9, 2012
    Publication date: October 23, 2014
    Applicant: Horizon Science Pty. Ltd.
    Inventors: David KANNAR, Barry James Kitchen
  • Publication number: 20140309439
    Abstract: The present document describes a method for extracting anthocyanin derivatives from a plant source. The method comprises the step of separating a homogenized extract of plant source in a polar acidified solvent for obtaining a residual solid, and a filtrate mixed with the acidified polar solvent. The separation includes a coarse filtration done by centrifugation of the plant source extract, by a filtration with a first filter having a pore size of about 100 ?m, and a fine filtration is done using a second filter having a pore size of about 10 ?m. Then, the filtrate mixed with the acidified polar solvent is evaporated for substantially separating the acidified polar solvent from the filtrate to obtain a semi-solid extract of anthocyanin derivatives.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 16, 2014
    Inventors: Sylvain Savard, André Tremblay, Michel Arsenault
  • Patent number: 8846751
    Abstract: This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1), wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition said units of flavan-3-ol being bonded each other in any one of three patterns as follows; (i) a bond between carbon at the position 4 and carbon at the position 8, (ii) a bond between carbon at the position 4 and carbon at the position 6, (iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon, at the position 2 and oxygen at the position 7.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 30, 2014
    Assignees: Miyazaki Enterprise Promotion Organization, Miyazaki Prefecture, Unkai Shuzo Co., Ltd., Minami Nippon Dairy Co-Op Co., Ltd.
    Inventors: Masahiko Takeshita, Hirohito Tsubouchi, Hirofumi Uto, Hiroaki Kataoka, Takanori Kai, Hideaki Hirabaru, Miho Sakai, Ena Akamatsu
  • Publication number: 20140275068
    Abstract: The present invention provides neuronal gap junction blocking compounds according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein the integers Q, R2, A, R1, Z1, Z2, and Z3 are as defined in claim 1. The compounds are useful for the treatment or prevention of a range of conditions including, e.g., migraine, epilepsy, non-epileptic seizures, brain injury, and cardiovascular disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Proximagen Limited
    Inventors: Edward Savory, Daniel Hill, Oldrich Kocian
  • Publication number: 20140256741
    Abstract: The present invention relates to compounds, compositions, and methods for treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more epicatechin derivatives in an amount effective to stimulate mitochondrial function in cells. The compounds, compositions, and methods described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.
    Type: Application
    Filed: August 6, 2012
    Publication date: September 11, 2014
    Applicant: Cardero Therapeutics, Inc.
    Inventors: Cyrus K. Becker, George F. Schreiner, Sundeep Dugar, Dinesh Mahajan
  • Publication number: 20140228434
    Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: UCB PHARMA GMBH
    Inventor: Claus MEESE
  • Publication number: 20140213802
    Abstract: A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicants: The Hong Kong Polytechnic University, McGill University, University of South Florida, Wayne State University
    Inventors: Tak-Hang CHAN, Wai-Har LAM, Larry Ming-Cheung CHOW, Qing Ping DOU, Deborah Joyce KUHN, Aslamuzzaman KAZI, Sheng Biao WAN, Kristin R. LANDIS-PIWOWAR
  • Publication number: 20140186315
    Abstract: The present invention provides a cosmetic composition containing one or more selected from a group consisting of green tea saponin and green tea polyphenol as active ingredients. The cosmetic composition of the invention is very safe to the skin and can greatly enhance biological mechanisms in the skin, and thus can serve as an anti-aging cosmetic composition.
    Type: Application
    Filed: August 20, 2012
    Publication date: July 3, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Hyun Seo Kang, Seung Hyun Kang, Ji Hyun Kim, Ji Seong Kim, Yong Joo Na, Byung Geun Chae, Sang Hoon Han
  • Publication number: 20140179774
    Abstract: The present invention relates to methods of treating one or more symptoms of a SHC-1/p66-related disease, inhibiting ROS generation or for the manufacture of a medicament in the above-mentioned treatment.
    Type: Application
    Filed: December 26, 2012
    Publication date: June 26, 2014
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Shau-Feng CHANG, Chun-Hsien MA, Kuo-Yi YANG
  • Publication number: 20140171631
    Abstract: The present invention relates generally to catechin and epicatechin conjugates of formula (I). For example, a chemical synthesis process for the preparation of catechin and epi-catechin compounds, in particular of catechin and epi-catechin conjugates is disclosed. A further aspect of the invention pertains to new catechin and epi-catechin conjugate compounds.
    Type: Application
    Filed: August 7, 2012
    Publication date: June 19, 2014
    Applicant: Nestec S.A.
    Inventors: Lucas Actis Goretta, Florian Viton, Denis Marcel Baron, Fabiola Dionisi
  • Patent number: 8742140
    Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: June 3, 2014
    Assignee: UCB Pharma GmbH
    Inventor: Claus Meese
  • Patent number: 8716497
    Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 6, 2014
    Assignees: Children's Hospital Medical Center, Ausio Pharmaceuticals, Inc.
    Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
  • Publication number: 20140121388
    Abstract: The object of the present invention is to provide an anti-obesity agent which contains a tea-derived component and which is safe and does not compromise the flavor of foods and beverages. According to the present invention, a safe and palatable anti-obesity agent can be provided by incorporating a benzotropolone ring-containing compound which has tea-derived, high inhibitory activities against lipase and alfa-glucosidase. The anti-obesity agent of the present invention does not compromise the flavor of foods and beverage, has palatability, and can be used in various use applications including foods and beverages intended for health enhancement such as reduction in triglycerides.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 1, 2014
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Yuko FUKUI, Sumio ASAMI, Mitsuru MAEDA
  • Patent number: 8710248
    Abstract: A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: April 29, 2014
    Assignees: The Hong Kong Polytechnic University, Wayne State University, University of South Florida, McGill University
    Inventors: Tak-Hang Chan, Wai-Har Lam, Larry Ming-Cheung Chow, Qing Ping Dou, Deborah Joyce Kuhn, Aslamuzzaman Kazi, Sheng Biao Wan, Kristin R. Landis-Piwowar